Feedback / Questions
CLSP-1025 - Clasp Therapeutics
https://www.businesswire.com/news/home/20241107258270/en/Clasp-Therapeutics-Presents-Comprehensive-Preclinical-Data-Validating-First-in-Class-Precision-T-Cell-Engager-Against-p53-Mutant-Solid-Tumors-at-SITC-Annual-Meeting
Nov 7, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next